Absci Reports Q3 2026 Financial Results and Clinical Updates for ABS-201
Absci Corporation (ABSI) reported third-quarter 2026 revenue of $304,000, a decrease from $378,000 in the prior-year period. The company recorded a net loss of $33.3 million, or $0.19 per share, driven by increased research and development expenses totaling $23.6 million as it advances its internal programs. Despite the losses, Absci maintains a strong cash position of $173.7 million, which management expects will fund operations through the second half of 2028. The company is heavily focused on its lead candidate, ABS-201, targeting pattern hair loss (PHL) and endometriosis. Management anticipates interim proof-of-concept data for PHL in December 2026, with full results expected in early 2027. Furthermore, Absci plans to initiate a Phase 2 trial for endometriosis in mid-2027, targeting a market opportunity that could see peak sales exceeding $4 billion if successful.
Tickers: $ABSI
Topics: Cash runway Clinical trial timeline Net loss R&D expenses Revenue decrease
Read the full article at Motley Fool
Part of the story Absci Reports Q3 2026 Financial Results and Clinical Updates for ABS-201 (4 articles)